Suzanne Rivera named new VP for research

Provost W.A. "Bud" Baeslack III announced, on November 4th, the appointment of Suzanne M. Rivera as Case Western Reserve´s new vice president for research, effective this month. Rivera, the university´s associate vice president for research since January 2011, emerged as the top choice after an extensive process involving campuswide nominations of internal university candidates. Since coming to CWRU, Rivera has distinguished herself through a commitment to collaboration and a focus on systems and processes.
Read more about her.


Research Matters

Click here to view previous editions of Research Matters and Research News and Updates.




Latest News

Research Newsletter
December 9, 2014  

National Multiple Sclerosis Society

The Barancik Prize for Innovation in Multiple Sclerosis Research recognizes an exceptional scientist or a team of scientists whose work in MS research has demonstrated outstanding innovation and originality.

The prize is administered by the National Multiple Sclerosis Society. A selection committee comprised of leaders in science, medicine, and MS advocacy will review nominees. The committee will evaluate:
• Exceptional innovation and originality in scientific research relevant to MS
• Impact and potential of the research to lead to pathways for the treatment and cure for MS
• Scientific accomplishments that merit recognition as a future leader in MS research

For more information and guidelines , visit the Society’s website.

 
Ohio Third Frontier (OTF), Ohio Development Services Agency

The goal of the Ohio Third Frontier Technology Validation and Start-Up Fund (TVSF) is to increase economic growth in Ohio through start-up companies that commercialize technologies developed by Ohio institutions of higher education and other Ohio not-for-profit research institutions. Two separate mechanisms have been set up to achieve these goals:

Phase 1 –Technology Validation The specific objectives of this phase are as follows:
• To generate the proof needed to move technology to the point that it is either ready to be licensed by an Ohio start-up company or otherwise deemed unfeasible for commercialization.
• To fund validation activities, such as prototyping, demonstrations, and assessment of critical failure points in subsequent development, scale-up, and commercialization.

Phase 2 – Start-Up Funds The specific objectives of this phase are as follows:
• To support Ohio start-up companies that have licensed technology developed at Ohio research institutions during the critical early life of the company, and accelerate the time to market of this technology.
• To generate the proof needed to either commercialize the technology or move the technology to the point where additional funds needed for commercialization can be raised.
• To fund activities in order to generate the needed proof.

The TVSF will support technology that falls within the following areas: Advanced Materials related to advanced polymers, ceramics, composites, carbon fibers and nanotubes and specialty metals and alloys; Aeropropulsion Power Management; Agribusiness and Food Processing; Fuel Cells and Energy Storage; Medical Technology related to imaging, surgical instruments/equipment, implant devices, and regenerative medicine; Software Applications for business and healthcare; Sensing and Automation Technologies; Situational Awareness and Surveillance Systems; Solar Photovoltaics; and Shale.

Potential CWRU Applicants - Contact:
Michael Haag, MS, MBA, Executive Director, Technology Management, 216-368-6106 or mhaag@case.edu.

For more information on the TVSF visit the Ohio Third Frontier website.

 
Pilot Grants Available from CGREAL

The Center for Genetic Research Ethics and Law (CGREAL) is currently accepting applications for pilot projects from Case Western Reserve University and Cleveland Clinic faculty who are interested in developing research on:

  • Ethical, legal, and social issues (ELSI) in the design and conduct of human genetic research, or
  • The translation of research results into clinical medicine, public health, and health policy needs related to genetics.
These grants are designed to support exploratory efforts towards the development of larger scholarly projects or lines of research related to CGREAL’s mission to facilitate interdisciplinary inquiry into the ethical, legal, and social implications of new advances in genetic and genomic science.

Criteria for evaluation will focus on the potential for expanding and enriching the range of perspectives being brought to genetic research ethics and law at CGREAL. Preference will be given to projects that are deemed likely to foster further collaborative research opportunities.

Requests may be made for up to $5,000. Funds may not be used for faculty salary support. Applications are encouraged from Case Western University and Cleveland Clinic faculty at any rank/level.

Applications will be accepted on a rolling basis and funding for awarded seed grants will be available immediately upon project approval.

Interested faculty should contact Aaron Goldenberg (aaron.goldenberg@case.edu or 216-368-8729).

For further information on the Center for Genetic Research Ethics and Law, see http://www.case.edu/med/bioethics/cgreal/ .

 
Avoiding Problems with Suspension and Debarment

Federal regulations require Case Western Reserve University to conduct business only with vendors, subcontractors, subawardees and individuals who are in good standing with the federal government. Anyone who is not in good standing with federal agencies cannot work on or provide services for government grants or contracts. People and entities who are subject to these restrictions are generally described as having been "debarred," "suspended" or "excluded."

To avoid inadvertent problems, visit http://www.sam.gov and verify that study staff, collaborators and vendors are not debarred, suspended or otherwise ineligible to receive federal funds.

 

Case Comprehensive Cancer Center

All Faculty members are invited to submit concept proposals for 5 year Projects to compete for incorporation as a full project proposal in the upcoming GI SPORE competing renewal application that will be prepared starting in January 2015 for submission in September 2015 All proposals must be directed towards translational research of a GI malignancy, with at least one specific aim that involves direct study of patients or of human tissues.

Proposals must include two project leaders; one Basic Science leader and one Clinical leader. Maximum Funding Level – $185,000/year direct cost for 5 years ($925,000 total direct costs).

Completed proposals must be emailed to John Pounardjian, hxp125@case.edu. For more information on GI SPORE, visit the CaseCCC website.

 

If you have news or information that you wish to have included in this update, please send it via e-mail to Tracy Wilson-Holden at tracy.wilson-holden@case.edu no later than 5 pm on the Monday of the week that the update is to be distributed. If you know of individuals who may be interested in receiving this update, please forward this e-mail to them. To subscribe or unsubscribe to Case Research News, email your request to Tora Williams at tora.williams@case.edu.

Please note: At the time of this transmission, all links functioned. However, Case Research News cannot guarantee that the information will not move or be deleted.